AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2024
Apr 9, 2024
34564_dirs_2024-04-08_bfdd5cfc-d2e7-4e0a-92ff-ebda7f68ea86.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2024-03-14
Reporting Person: O'Neill Vincent (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-14 | Common Stock | M | 521 | — | Acquired | 3323 | Direct |
| 2024-03-15 | Common Stock | M | 2250 | — | Acquired | 5573 | Direct |
| 2024-04-04 | Common Stock | S | 165 | $2.6211 | Disposed | 5408 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-14 | Restricted Stock Units | $ | M | 521 | Disposed | Common Stock (521) | Direct | |
| 2024-03-15 | Restricted Stock Units | $ | M | 2250 | Disposed | Common Stock (2250) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
F3: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.